A Phase 1, Open-Label Study To Evaluate 5-Ht6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11c]Pf-04171252 Following Single Oral Dose Administration Of Pf-05212377 (Sam-760) In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2011
At a glance
- Drugs PF 5212377 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.